Related Experiment Video
Updated: Jan 9, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Assay of Efanesoctocog Alfa in 200 Centres: Data From Collaborative NEQAS BC (United Kingdom) and ECAT (Netherlands)
Christopher Reilly-Stitt1, Piet Meijer2, Ian Jennings1
1UK NEQAS (Blood Coagulation), Sheffield, UK.
Background:
Efanesoctocog alfa (EFA) is an ultra-long half-life FVIII product. However, measuring the level of EFA using standard one stage (OSA) and Chromogenic assays (CA) is affected by both underestimation and overestimation when using some commonly used APTT reagents for OSA and overestimation when using CA assays.
Objectives:
ECAT and NEQAS BC distributed samples containing EFA to centres for measurement of EFA using assays available locally. The aim was to provide method specific data and recommendations for additional OSA or CA assays.
Methods:
In Autumn 2024, four samples with levels of EFA between 5 and 100 IU/dL (based on potency label) were buffered and lyophilized for distribution to 300 hospital and university laboratories.
Results:
Two-hundred participants returned 174 OSA and 148 CA results for samples EFA 24:01-24:04. Twelve different APTT reagents, six were used by (n ≥ 10) and 10 different chromogenic assays were employed, of which four were used by (n ≥ 10).
Conclusion:
The NEQAS BC and ECAT exercise confirmed the field study: over-estimation for Actin FS OSA and all CA assays at all EFA levels plus an under-estimation for SynthasIL OSA at EFA levels of: 20, 50 and 100 IU/dL. Centres using Actin FSL on a Siemens/Sysmex or Stago analyser plus centres using Synthafax on a Werfen analysers had median recoveries within ±25% compared to the assigned potency for samples at EFA levels of: 20; 50 and 100 IU/dL. Centres using CK Prest and Pathromtin had median recoveries within ±25% compared to the assigned potency for samples at an EFA levels of 100 IU/dL.
